Developer docs
API playgroundTry for free, no card

Search company profiles

Single Cell Technology, Inc.

Full company profile

uuid000bmaf

Namestring
Single Cell Technology, Inc.
Legal namestring
Single Cell Technology, Inc.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Single Cell Technology, Inc. is a San Jose, California-based contract research organization founded in 2008 that began commercial antibody discovery operations in 2016. The company provides B2B antibody discovery services to large pharmaceutical companies (including top 10 pharma) and small virtual biotech firms across therapeutic areas spanning immuno-oncology, central nervous system diseases, infectious disease, and autoimmune conditions. The company operates with a 1-10 person team under founder Chun-Nan Chen, who serves concurrently as CEO and CSO, with Erik Babajanian as CFO.

The company's technical core is the proprietary AbTheneum™ platform — a single B cell antibody discovery system that screens antibodies in parallel using three integrated components: picoliter well deposition (20,000+ cells placed in wells under 200 picoliters each), antibody array capture on slides for multiplex fluorescent screening (antigen binding, epitope specificity, cross-reactivity, blocking), and a custom DNA microarray that sequences thousands of full-length IgG sequences in parallel via barcodes and clonotype clustering. The architecture is designed to eliminate the picking bias inherent to hybridoma and phage display workflows. Add-on capabilities include SurfScreen for membrane-bound targets (GPCRs, virus-like particles), First Look Assay for low-cost pre-campaign evaluation, and integrated cell-based functional bioassays including ADCC reporter assays and PBMC-based validation.

Revenue is generated through fee-for-service antibody discovery campaigns. Clients submit target antigens and engage Single Cell Technology to design and execute screening campaigns, receiving antibody candidates with full-length sequences, screening data, and characterization packages — typically delivered as a complete data package within three weeks of cell harvest, with reported >98% success rate on antigen binding after expression. Go-to-market is sales-led direct engagement with pharma discovery and translational teams rather than channel partners, supported by scientific content marketing (case studies, conference presentations at Antibody Engineering & Therapeutics, webinars). The company holds a core technology alliance with Miltenyi Biotec for cell isolation workflows including B cell isolation kits and MACSQuant Tyto cell sorting, enabling human PBMC-based campaigns in addition to standard murine, rat, and rabbit host systems. The company has received a single early-stage funding tranche of $323,777 (2012, investors undisclosed) and remains privately held with no disclosed institutional venture capital.

Short descriptiontext

Single Cell Technology, Inc. is a San Jose-based biotech contract research organization providing fee-for-service antibody discovery through its proprietary AbTheneum™ single B cell screening platform, serving top 10 pharmaceutical companies and small virtual biotechs across immuno-oncology, CNS, infectious disease, and autoimmune therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Jose, United States
HQ citystring
San Jose
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery services, single B cell screening, therapeutic antibody discovery, immunoglobulin sequencing, biopharma research services
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Antibody Discovery Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Antibody Discovery Services
TypeProfessional Services
Description

Fee-for-service antibody discovery campaigns using the AbTheneum platform. Clients submit target antigens and receive antibody candidates with full-length sequences, screening data, and characterization. Pricing is likely project-based based on campaign complexity.

singlecelltechnology.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1AbTheneum
Description

Single Cell Technology's proprietary platform for single B cell antibody discovery that screens all antibodies in parallel for multiple parameters without picking bias.

singlecelltechnology.com
Core offering1 text field

Single Cell Technology provides fee-for-service antibody discovery using its proprietary AbTheneum™ platform, which deposits single B cells into picowells, captures their secreted antibodies on slides within hours, and sequences full-length IgG using a custom DNA microarray. Clients submit target antigens and receive antibody candidates with full-length sequences, multi-layered screening data (antigen binding, epitope, cross-reactivity, blocking), and functional characterization in approximately three weeks.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Single Cell Technology offers a unified antibody discovery platform centered on AbTheneum™, with specialized add-on modules including SurfScreen for membrane target screening and First Look Assay for pre-campaign sample evaluation. The company also provides various screening assay capabilities including epitope binning, blocking assays, competition assays, and cell-based functional bioassays.

Product and service3 records
1AbTheneum™ Antibody Discovery Platform
CategoryCore antibody discovery service
Description

Single B cell antibody discovery service that screens antibodies secreted by cells within hours using picoliter picowell technology, captures full-length IgG sequences on a custom DNA microarray, and delivers candidates with multi-parameter screening data (antigen binding, epitope, cross-reactivity, blocking) in about three weeks for pharmaceutical and biotech clients.

2SurfScreen
CategoryMembrane target screening add-on
Description

Module of the AbTheneum platform for screening antibodies against membrane targets using cell-based screens, combining cell-based and recombinant (SimulScreen) approaches to enrich data for membrane-bound antigens.

3First Look Assay
CategoryPre-campaign screening service
Description

Low-cost, small-scale antibody screening study performed on multiple samples before a full AbTheneum campaign, using the platform's cell isolation and antibody screening for sample comparison and go/no-go decisions.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration with Miltenyi Biotec for cell isolation workflows. Miltenyi sourced peripheral mononuclear blood cells (PBMCs) from donors and provided the Class-Switched Memory B Cell Isolation Kit (catalog # 130-093-617) and B Cell Expansion Kit (catalog # 130-106-196). The partnership enables AbTheneum to work with human cells using Miltenyi's MACSQuant Tyto cell sorter for antigen-specific cell enrichment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Single Cell Technology, Inc.

Antibody Discovery Servicessinglecelltechnology.com

Single Cell Technology, Inc. is a San Jose-based biotech contract research organization providing fee-for-service antibody discovery through its proprietary AbTheneum™ single B cell screening platform, serving top 10 pharmaceutical companies and small virtual biotechs across immuno-oncology, CNS, infectious disease, and autoimmune therapeutic areas.

What Single Cell Technology, Inc. does

Single Cell Technology, Inc. is a San Jose, California-based contract research organization founded in 2008 that began commercial antibody discovery operations in 2016. The company provides B2B antibody discovery services to large pharmaceutical companies (including top 10 pharma) and small virtual biotech firms across therapeutic areas spanning immuno-oncology, central nervous system diseases, infectious disease, and autoimmune conditions. The company operates with a 1-10 person team under founder Chun-Nan Chen, who serves concurrently as CEO and CSO, with Erik Babajanian as CFO.

The company's technical core is the proprietary AbTheneum™ platform — a single B cell antibody discovery system that screens antibodies in parallel using three integrated components: picoliter well deposition (20,000+ cells placed in wells under 200 picoliters each), antibody array capture on slides for multiplex fluorescent screening (antigen binding, epitope specificity, cross-reactivity, blocking), and a custom DNA microarray that sequences thousands of full-length IgG sequences in parallel via barcodes and clonotype clustering. The architecture is designed to eliminate the picking bias inherent to hybridoma and phage display workflows. Add-on capabilities include SurfScreen for membrane-bound targets (GPCRs, virus-like particles), First Look Assay for low-cost pre-campaign evaluation, and integrated cell-based functional bioassays including ADCC reporter assays and PBMC-based validation.

Revenue is generated through fee-for-service antibody discovery campaigns. Clients submit target antigens and engage Single Cell Technology to design and execute screening campaigns, receiving antibody candidates with full-length sequences, screening data, and characterization packages — typically delivered as a complete data package within three weeks of cell harvest, with reported >98% success rate on antigen binding after expression. Go-to-market is sales-led direct engagement with pharma discovery and translational teams rather than channel partners, supported by scientific content marketing (case studies, conference presentations at Antibody Engineering & Therapeutics, webinars). The company holds a core technology alliance with Miltenyi Biotec for cell isolation workflows including B cell isolation kits and MACSQuant Tyto cell sorting, enabling human PBMC-based campaigns in addition to standard murine, rat, and rabbit host systems. The company has received a single early-stage funding tranche of $323,777 (2012, investors undisclosed) and remains privately held with no disclosed institutional venture capital.

Single Cell Technology, Inc. firmographics

Firmographics
Name
Single Cell Technology, Inc.
Legal name
Single Cell Technology, Inc.
Website
https://singlecelltechnology.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Single Cell Technology, Inc. is a San Jose-based biotech contract research organization providing fee-for-service antibody discovery through its proprietary AbTheneum™ single B cell screening platform, serving top 10 pharmaceutical companies and small virtual biotechs across immuno-oncology, CNS, infectious disease, and autoimmune therapeutic areas.
Ownership category
akta.pro rank

Single Cell Technology, Inc. industry classification

Industry
Product category
Antibody Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody discovery services
  • Single B cell screening
  • Therapeutic antibody discovery
  • Immunoglobulin sequencing
  • Biopharma research services

Where Single Cell Technology, Inc. is headquartered

Location

Headquarters

HQ city
San Jose
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Single Cell Technology, Inc. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Antibody Discovery Services: Fee-for-service antibody discovery campaigns using the AbTheneum platform. Clients submit target antigens and receive antibody candidates with full-length sequences, screening data, and characterization. Pricing is likely project-based based on campaign complexity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Single Cell Technology, Inc. product offering

Product offering

Core offering

Single Cell Technology provides fee-for-service antibody discovery using its proprietary AbTheneum™ platform, which deposits single B cells into picowells, captures their secreted antibodies on slides within hours, and sequences full-length IgG using a custom DNA microarray. Clients submit target antigens and receive antibody candidates with full-length sequences, multi-layered screening data (antigen binding, epitope, cross-reactivity, blocking), and functional characterization in approximately three weeks.

Product overview

Single Cell Technology offers a unified antibody discovery platform centered on AbTheneum™, with specialized add-on modules including SurfScreen for membrane target screening and First Look Assay for pre-campaign sample evaluation. The company also provides various screening assay capabilities including epitope binning, blocking assays, competition assays, and cell-based functional bioassays.

Differentiator

Problem solved

Functional benefit

Brands

  • AbTheneum: Single Cell Technology's proprietary platform for single B cell antibody discovery that screens all antibodies in parallel for multiple parameters without picking bias.

Products and services

  • AbTheneum™ Antibody Discovery Platform Single B cell antibody discovery service that screens antibodies secreted by cells within hours using picoliter picowell technology, captures full-length IgG sequences on a custom DNA microarray, and delivers candidates with multi-parameter screening data (antigen binding, epitope, cross-reactivity, blocking) in about three weeks for pharmaceutical and biotech clients.
  • SurfScreen Module of the AbTheneum platform for screening antibodies against membrane targets using cell-based screens, combining cell-based and recombinant (SimulScreen) approaches to enrich data for membrane-bound antigens.
  • First Look Assay Low-cost, small-scale antibody screening study performed on multiple samples before a full AbTheneum campaign, using the platform's cell isolation and antibody screening for sample comparison and go/no-go decisions.

Companies that use Single Cell Technology, Inc.

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Single Cell Technology, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Single Cell Technology, Inc. partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Miltenyi BioteccoreTechnology or IntegrationCollaboration with Miltenyi Biotec for cell isolation workflows. Miltenyi sourced peripheral mononuclear blood cells (PBMCs) from donors and provided the Class-Switched Memory B Cell Isolation Kit (catalog # 130-093-617) and B Cell Expansion Kit (catalog # 130-106-196). The partnership enables AbTheneum to work with human cells using Miltenyi's MACSQuant Tyto cell sorter for antigen-specific cell enrichment.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Single Cell Technology, Inc. competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Single Cell Technology, Inc. social profiles

Digital presence

Single Cell Technology, Inc. compliance and trust

Trust signal

Compliance2 records

Single Cell Technology, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Single Cell Technology, Inc. leadership team

Management profile

Number of profiles

Profiles2 records

Single Cell Technology, Inc. funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Single Cell Technology, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Single Cell Technology, Inc.

What does Single Cell Technology, Inc. do?

Single Cell Technology provides fee-for-service antibody discovery using its proprietary AbTheneum™ platform, which deposits single B cells into picowells, captures their secreted antibodies on slides within hours, and sequences full-length IgG using a custom DNA microarray. Clients submit target antigens and receive antibody candidates with full-length sequences, multi-layered screening data (antigen binding, epitope, cross-reactivity, blocking), and functional characterization in approximately three weeks.

Is Single Cell Technology, Inc. a public or private company?

Single Cell Technology, Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Single Cell Technology, Inc. founded?

Single Cell Technology, Inc. was founded in 2008. It employs 11 to 50 people.

Where is Single Cell Technology, Inc. based?

Single Cell Technology, Inc. is headquartered in San Jose, United States, in the North America region.

How does Single Cell Technology, Inc. make money?

One revenue line is on record: antibody Discovery Services.

Does Single Cell Technology, Inc. have an API?

No public API is recorded for Single Cell Technology, Inc..

What industry is Single Cell Technology, Inc. in?

Single Cell Technology, Inc.'s product category is Antibody Discovery Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales